Free Trial

Emmanuel Papadakis Analyst Performance

Analyst at Deutsche Bank Aktiengesellschaft

Emmanuel Papadakis is a stock analyst at Deutsche Bank Aktiengesellschaft in the healthcare sector, covering 6 publicly traded companies. Over the past year, Emmanuel Papadakis has issued 2 stock ratings, including buy and sell recommendations. While full access to Emmanuel Papadakis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emmanuel Papadakis' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 9 Years
Buy Recommendations
37.50% 6 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy37.5%6 ratings
Hold43.8%7 ratings
Sell18.8%3 ratings

Out of 16 total stock ratings issued by Emmanuel Papadakis at Deutsche Bank Aktiengesellschaft, the majority (43.8%) have been Hold recommendations, followed by 37.5% Buy and 18.8% Sell.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
3 companies
NASDAQ
33.3% of companies on NASDAQ
2 companies
OTCMKTS
16.7% of companies on OTCMKTS
1 company

Emmanuel Papadakis, an analyst at Deutsche Bank Aktiengesellschaft, currently covers 6 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
6 companies
100.0%

Emmanuel Papadakis of Deutsche Bank Aktiengesellschaft specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
5 companies
83.3%
BIOTECHNOLOGY
1 company
16.7%

Emmanuel Papadakis' Ratings History at Deutsche Bank Aktiengesellschaft

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Novartis AG stock logo
NVS
Novartis
10/30/2026Downgrade$161.59Sell
Sanofi stock logo
SNY
Sanofi
1/16/2026Reiterated Rating$46.58Buy
Sanofi stock logo
SNY
Sanofi
9/2/2025Upgrade$49.48Buy